A new combination of drugs slowed the growth of cancer cells by an unexpected mechanism that may one day lead to improved treatment of cervical cancer, a UT Southwestern-led study published in Molecular Cancer Research suggests.
Scientists at Baltic Federal University have suggested evaluating concentration and chemical composition of drugs by means of vibrational spectroscopy and nuclear magnetic resonance instead of conventional complex approaches
The U.S. Food and Drug Administration has approved the targeted imaging agent Cytalux (pafolacianine) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors completely while sparing healthy tissue. Thoracic surgeons at the Center for Precision Surgery in the Abramson Cancer Center at Penn Medicine led the clinical trials evaluating the imaging agent in lung cancer, in a partnership with On Target Laboratories.
Metformin, the most prescribed drug for treating diabetes mellitus, known as type 2 diabetes, requires the presence of the growth differentiation factor 15 (GDF15) —a protein whose expression increases in response to cellular stress— to present its antidiabetic effects.
With modern therapies for heart failure (HF) with reduced ejection fraction (HFrEF), some patients can improve their cardiac function during treatment.
The latest guidance in addressing proper monitoring and reversal of neuromuscular blockade drugs during general anesthesia – a major advance in patient safety and satisfaction – was published today in Anesthesiology, the American Society of Anesthesiologist’s (ASA) peer-reviewed medical journal.
Abhinav Jha, at the McKelvey School of Engineering, wants to use novel imaging to better understand how people absorb radiation therapy. His team won a four-year $2.2 million National Institutes of Health (NIH) grant for the study, which aims to guide treatment decisions.
As human lifespans increase, so does general memory impairment – calling for the need to expand research for dementia treatment. The key to this expansion is the center focus of the SLAS Discovery featured article, “A neuronal cell-based reporter system for monitoring the activity of HDAC2” by Unemura, et al.
An analysis of combined pharmacotherapy for reducing drinking and smoking validated findings that measuring reductions in the amount of drinking, not just abstinence, was an effective outcome for alcohol medication trials.
Pesquisadores da Mayo Clinic dizem que o anticorpo monoclonal bebtelovimabe (já autorizado pela Food and Drug Administration para uso emergencial na variante ômicron da COVID-19) é uma opção confiável para tratar a BA.2 e outras subvariantes da COVID-19. As descobertas do estudo retrospectivo realizado vários locais, envolvendo 3.607 pacientes de alto risco foram publicadas na revista médica Journal of Infectious Diseases.
Los investigadores de Mayo Clinic informan que el anticuerpo monoclonal bebtelovimab, ya autorizado por la Administración de Alimentos y Medicamentos de Estados Unidos para usar en emergencias de la variante ómicron de la COVID-19, es una alternativa confiable para tratar a la BA.2 y otras subvariantes de la COVID-19. Los resultados del estudio retrospectivo que se realizó en varios sitios con 3607 pacientes de alto riesgo se publicaron en Journal of Infectious Diseases (Revista de Enfermedades Infecciosas).
مدينة روتشستر، ولاية مينيسوتا - يقول باحثو مايو كلينك إن الجسم المضاد أحادي النسيلة ببتيلوفيماب، المُرخص بالفعل من قبل إدارة الغذاء والدواء الأمريكية للاستخدام في حالات الطوارئ الخاصة بمتحور أوميكرون من فيروس كورونا المستجد (كوفيد-19)، هو خيار موثوق لعلاج سلالة BA.2 والمتحورات الفرعية الأخرى لفيروس كورونا المستجد (كوفيد-19). ونتائج دراستهم الاسترجاعية متعددة المواقع والتي شملت 3,607 مريضًا معرضين لمخاطر عالية، منشورة في مجلة الأمراض المعدية.
A retrospective cohort study of more than 44,000 nonhospitalized persons diagnosed with COVID-19 found that nirmatrelvir plus ritonavir reduced the overall risk of hospitalization and death. The study is published in Annals of Internal Medicine.
Researchers from Tel Aviv University developed a new technology that will allow controlled encapsulation and release of molecules by exposure to UV light.
A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented by researchers from the University of Pennsylvania’s Abramson Cancer Center at the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract 565).
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped
"This is a very striking and significant result that essentially separates LIGHT from any of the other inflammatory cytokines that have been implicated in the process in severe asthmatics."
Johns Hopkins Medicine researchers continue their exploration into psychedelics and how these drugs may produce a wide range of profound changes in perception, cognition and mood.
For decades, doctors have treated kids with attention-deficit/hyperactivity disorder (ADHD) with methylphenidate, a stimulant drug sold as Ritalin and Concerta, making it one of the most widely prescribed medications aimed at the central nervous system.
The University of California, San Francisco, and Johns Hopkins University today expanded the UCSF-JHU Opioid Industry Documents Archive, adding one million pages of records from Insys Therapeutics—which manufactured and marketed the fentanyl spray Subsys.
Many pathogenic viruses, including herpesviruses, SARS -Cov-2, cytomegalovirus, papillomavirus, virus Nipah and others, use the similar mechanism to join the target cells, which consists in their attachment to heparan sulfate proteoglycan of the cell membrane.
According to a paper published in Chemical Engineering Journal recently, a team from the High Magnetic Field Laboratory (HMFL), Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences, successfully designed a safe and efficient nanotorpedo for the delivery of chemotherapeutic drugs.
People who take cholesterol-lowering drugs called statins may have a lower risk of having a type of stroke called an intracerebral hemorrhage, according to a new study published in the December 7, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. An intracerebral hemorrhage is caused by bleeding in the brain.
Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is designed in such a way that natural selection to maintain infectiousness of the virus should also maintain the drug’s activity against future variants.
Physician-scientists from Cedars-Sinai Cancer are available for comment on research being presented throughout the San Antonio Breast Cancer Symposium, taking place Dec. 6-10.
While many new medications designed to treat neurologic diseases have hit the market, utilization by patients remains low due to high costs and similar effectiveness to existing drugs, a new study funded by the American Academy of Neurology finds.
Teens with Type 1 diabetes (T1D) who took bromocriptine, a medication used to treat Parkinson’s disease and Type 2 diabetes, had lower blood pressure and less stiff arteries after one month of treatment compared to those who did not take the medicine, according to a small study published today in Hypertension, an American Heart Association journal.
A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine’s Abramson Cancer Center showed.
Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced the risk for hospitalization for any cause in patients with chronic kidney disease (CKD) with and without type 2 diabetes.
By simulating molecular dynamics, scientists from St. Jude Children’s Research Hospital revealed how the selectivity or promiscuity of GPCR coupling relies on the location and duration of intermolecular interactions.
Henry Ford Health Orthopedic researchers looked at steroids as part of a multi-modal pain control regimen and an alternative to using opioids after outpatient knee replacement. The study won the 2022 American Association of Hip and Knee Surgeons Clinical Research Award.
Researchers at The Tisch Cancer Institute uncovered inflammatory markers that may predict which COVID-19 patients are more likely to respond to therapies like the anti-cancer drug pacritinib, according to phase 2 trial results published in JAMA Network Open in December.
Scientists have created a much faster way to make certain complex molecules, which are widely used by pharmaceuticals for antibiotics and anti-fungal medicines.
A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity. DS-1211 is a potential first-in-class small molecule developed through a research collaboration between Daiichi Sankyo and Sanford Burnham Prebys.
While it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developing new breast cancers, a new computer modeling study led by researchers at Georgetown Lombardi Comprehensive Cancer Center and colleagues showed that these treatments could also reduce the risk of dying from the disease in women who are at high risk.
When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer’s drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease.
A number of new neurologic medications for diseases like multiple sclerosis (MS), Parkinson’s disease and migraine have received U.S. Food and Drug Administration (FDA) approval over the past decade. However, with most having higher out-of-pocket costs and benefits similar to existing, less expensive drugs, only a small percentage of people with neurologic conditions are being treated with these new drugs, according to a study funded by the American Academy of Neurology and published in the November 30, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.